X Bioscience Public Company (XBIO) Fair Value & Analysis
Consumer Defensive · TH · Market cap 972M THB
Fair value as of: Jun 26, 2026
From 1 valuation models · updated 3 days ago
Fair value updated Jun 26, 2026 — revised from 0.0500 THB to 0.0280 THB (−44.0%) since Jun 24, 2026. Share price −12.5% over the past month.
Price vs Fair Value (12 months)
12‑month range 0.0426 THB – 2.87 THB · fair‑value band 0.0280 THB – 0.0350 THB · the 0.0700 THB price screens above the 0.0280 THB fair value. As of Jun 26, 2026.
✦ Which stocks are undervalued right now? Check free Discover now →Analysis
X Bioscience Public Company (XBIO) currently trades at 0.0700 THB, while our model-based Fair Value estimate is 0.0280 THB — implying the stock looks roughly 60.0% overvalued today. We read business quality at 94/100 (high quality), in the Consumer Defensive sector. Bear case: priced above our estimate, the market already discounts strong expectations. Bull case: above-average quality can justify a premium — the entry price still matters most (evidence: low).
Trailing-twelve-month revenue stands at 159M THB. Revenue grew 55.6% year over year. Net debt stands at 188M THB. Fundamentals as of Jun 26, 2026
Key figures & financial health
More key figures
Figures from reported company fundamentals (EODHD) · as of Jun 26, 2026. TTM = trailing twelve months.
About the company
X Bioscience Public Company Limited, together with its subsidiaries, sells food and beverages in Thailand. It engages in the food and beverage investment and restaurant businesses. The company also manufactures and sells biological products, as well as generates and transmits electric power. Its brands include Kagonoya, Le Boeuf, and Bake Cheese Tart. The company was formerly known as Wow Factor Public Company Limited and changed its name to X Bioscience Public Company Limited in January 2025. X Bioscience Public Company Limited was founded in 1984 and is headquartered in Bangkok, Thailand.
Revenue & earnings trend
FY2021 – FY2025 · reported fiscal years
X Bioscience Public Company reported revenue of 130M THB in FY2025 versus 412M THB in FY2021, a compound −25.1%/yr. Reported net income was −469M THB in FY2025.
Open the full interactive analysis →
Similar stocks
6 more Food Distribution stocks, each showing price versus our Fair Value estimate (as of Jun 26, 2026).
| Stock | Price | Fair Value | vs Fair Value |
|---|---|---|---|
| Sysco Corporation SYY | $77.98 | $60.42 | -23% |
| US Foods Holding USFD | $92.76 | $54.78 | -41% |
| Performance Food Group PFGC | $104.39 | $45.48 | -56% |
| Jerónimo Martins, SGPS, S.A JRONF | $23.70 | $24.02 | +1% |
| Bunzl plc BZLFY | $17.22 | $19.33 | +12% |
| Bid Corporation BPPPF | $25.52 | $27.44 | +8% |
Explore undervalued stocks
More undervalued Consumer Defensive stocks →
Frequently asked questions
Is X Bioscience Public Company (XBIO) undervalued?
What is the fair value of XBIO?
What is the quality score of XBIO?
What is the revenue of X Bioscience Public Company (XBIO)?
What is the net profit margin of XBIO?
How we calculate Fair Value
Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data — nothing guessed.
Educational research only · not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.